Mette Vesterhus
- Professor; MD, PhD
Education
PhD University of Bergen, 2009
MD University of Bergen, 1999
Norwegian clinical specialist accreditations
"Indremedisin" (Internal medicine), "Fordøyelsessykdommer" (Gastroenterology)
Current and recent positions
2018-present: Associate Professor (50%), University of Bergen
2018-present: Senior consultant, Haraldsplass Deaconess Hospital, Bergen
2016-present: Group leader, Clinical group Bergen, Norwegian PSC Research Center, OUH Rikshospitalet
2012-2018: Post.doc., Norwegian PSC Research Center, OUH Rikshospitalet and National Center of Excellence for Ultrasound in Gastroenterology, Dept. of Medicine, Haukeland University Hospital, Bergen
2009-2017: Clinical fellow in gastroenterology (50%), Dept. of Medicine, Haukeland University Hospital, Bergen
2006-2007: Visiting PhD Research fellow (12 months), Harvard Medical School, Boston, USA
Research interest
Primary sclerosing cholangitis. Biomarkers of disease activity and prognosis. Liver fibrosis. Elastography. Imaging in PSC. Prospective cohorts. Clinical trials.
Publications 2024
Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis
BMJ Open, 14 (6), e080143
DOI 10.1136/bmjopen-2023-080143, PubMed 38926149
Publications 2023
Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation
J Hepatol, 79 (4), 955-966
DOI 10.1016/j.jhep.2023.05.038, PubMed 37328069
[Primary sclerosing cholangitis]
Tidsskr Nor Laegeforen, 143 (17)
DOI 10.4045/tidsskr.23.0156, PubMed 37987062
Noninvasive evaluation of fibrosis in adult biliary diseases
Curr Opin Gastroenterol, 39 (2), 83-88
DOI 10.1097/MOG.0000000000000909, PubMed 36821455
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
J Hepatol, 79 (1), 93-108
DOI 10.1016/j.jhep.2023.02.027, PubMed 36868481
Whole blood RNA sequencing identifies transcriptional differences between primary sclerosing cholangitis and ulcerative colitis
JHEP Rep, 6 (2), 100988
DOI 10.1016/j.jhepr.2023.100988, PubMed 38304234
Publications 2022
Impact on follow-up strategies in patients with primary sclerosing cholangitis
Liver Int, 43 (1), 127-138
DOI 10.1111/liv.15286, PubMed 35535655
Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis
JHEP Rep, 4 (11), 100561
DOI 10.1016/j.jhepr.2022.100561, PubMed 36176935
Improvement of cholestatic episodes in patients with benign recurrent intrahepatic cholestasis (BRIC) treated with rifampicin. A long-term follow-up
Scand J Gastroenterol, 58 (5), 512-520
DOI 10.1080/00365521.2022.2143725, PubMed 36369734
Highly Increased Levels of Inter-α-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases
J Clin Transl Hepatol, 10 (5), 796-802
DOI 10.14218/JCTH.2021.00515, PubMed 36304505
Algebraic topology-based machine learning using MRI predicts outcomes in primary sclerosing cholangitis
Eur Radiol Exp, 6 (1), 58
DOI 10.1186/s41747-022-00312-x, PubMed 36396865
[Good TIPS for severe liver disease]
Tidsskr Nor Laegeforen, 142 (14)
DOI 10.4045/tidsskr.22.0585, PubMed 36226424
[We need a new strategy for liver disease]
Tidsskr Nor Laegeforen, 142 (3)
DOI 10.4045/tidsskr.21.0892, PubMed 35170917
Publications 2021
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
Clin Transl Gastroenterol, 12 (3), e00315
DOI 10.14309/ctg.0000000000000315, PubMed 33646203
Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis
Scand J Gastroenterol, 56 (4), 443-452
DOI 10.1080/00365521.2021.1880627, PubMed 33583308
Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF
JHEP Rep, 3 (5), 100328
DOI 10.1016/j.jhepr.2021.100328, PubMed 34485881
Controlled Attenuation Parameter in Healthy Individuals Aged 8-70 Years
Ultrasound Int Open, 7 (1), E6-E13
DOI 10.1055/a-1461-4714, PubMed 33969259
[Diagnosis and treatment of autoimmune hepatitis]
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.20.1045, PubMed 34182737
Publications 2020
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
Clin Gastroenterol Hepatol, 18 (10), 2295-2304.e2
DOI 10.1016/j.cgh.2020.02.014, PubMed 32068151
Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis
Gastroenterology, 160 (5), 1784-1798.e0
DOI 10.1053/j.gastro.2020.12.058, PubMed 33387530
Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group
J Hepatol, 73 (6), 1496-1506
DOI 10.1016/j.jhep.2020.07.023, PubMed 32707224
Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
J Hepatol, 74 (3), 755-756
DOI 10.1016/j.jhep.2020.11.031, PubMed 33309116
Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems
Ultrasound Med Biol, 46 (8), 1854-1864
DOI 10.1016/j.ultrasmedbio.2020.03.025, PubMed 32507342
Liver Elastography in Healthy Children Using Three Different Systems - How Many Measurements Are Necessary?
Ultraschall Med, 43 (5), 488-497
DOI 10.1055/a-1283-5906, PubMed 33348414
Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults
Ultrasound Int Open, 6 (3), E54-E61
DOI 10.1055/a-1298-9642, PubMed 33305164
Correction: Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults
Ultrasound Int Open, 6 (3), E66
DOI 10.1055/a-1340-1260, PubMed 33426423
Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities
J Gastroenterol, 55 (6), 588-614
DOI 10.1007/s00535-020-01681-z, PubMed 32222826
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease
JHEP Rep, 3 (1), 100178
DOI 10.1016/j.jhepr.2020.100178, PubMed 33225252
Publications 2019
Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis
Sci Rep, 9 (1), 8450
DOI 10.1038/s41598-019-44762-7, PubMed 31186435
Normal Liver Stiffness Values in Children: A Comparison of Three Different Elastography Methods
J Pediatr Gastroenterol Nutr, 68 (5), 706-712
DOI 10.1097/MPG.0000000000002320, PubMed 30889132
Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis
Eur J Clin Invest, 49 (5), e13088
DOI 10.1111/eci.13088, PubMed 30762236
Publications 2018
Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis
Liver Int, 39 (2), 371-381
DOI 10.1111/liv.13979, PubMed 30269440
Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning
Hepatology, 71 (1), 214-224
DOI 10.1002/hep.30085, PubMed 29742811
Repeatability of shear wave elastography in liver fibrosis phantoms-Evaluation of five different systems
PLoS One, 13 (1), e0189671
DOI 10.1371/journal.pone.0189671, PubMed 29293527
Liver elasticity in healthy individuals by two novel shear-wave elastography systems-Comparison by age, gender, BMI and number of measurements
PLoS One, 13 (9), e0203486
DOI 10.1371/journal.pone.0203486, PubMed 30216377
Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis
Aliment Pharmacol Ther, 48 (2), 179-189
DOI 10.1111/apt.14806, PubMed 29851098
Publications 2017
Assessing Liver Stiffness by 2-D Shear Wave Elastography in a Healthy Cohort
Ultrasound Med Biol, 44 (2), 332-341
DOI 10.1016/j.ultrasmedbio.2017.10.013, PubMed 29249457
Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study
Liver Int, 37 (10), 1554-1561
DOI 10.1111/liv.13402, PubMed 28267887
Primary sclerosing cholangitis - a comprehensive review
J Hepatol, 67 (6), 1298-1323
DOI 10.1016/j.jhep.2017.07.022, PubMed 28802875
Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis
J Hepatol, 66 (6), 1214-1222
DOI 10.1016/j.jhep.2017.01.019, PubMed 28161472
Publications 2016
Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis
Liver Int, 37 (3), 458-465
DOI 10.1111/liv.13238, PubMed 27558072
Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis
Gut, 66 (1), 137-144
DOI 10.1136/gutjnl-2016-311739, PubMed 27406039
Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation
Mucosal Immunol, 9 (6), 1455-1465
DOI 10.1038/mi.2016.18, PubMed 26982597
The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls
Gut, 66 (4), 611-619
DOI 10.1136/gutjnl-2015-310500, PubMed 26887816
Elevated trimethylamine-N-oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function
United European Gastroenterol J, 5 (4), 532-541
DOI 10.1177/2050640616663453, PubMed 28588885
Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis
Ultrasound Med Biol, 42 (9), 2146-55
DOI 10.1016/j.ultrasmedbio.2016.04.016, PubMed 27262519
In Vitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain and Shear Wave Technology
Ultrasound Med Biol, 42 (11), 2572-2588
DOI 10.1016/j.ultrasmedbio.2016.07.002, PubMed 27570209
Prognostic biomarkers and surrogate end points in PSC
Liver Int, 36 (12), 1748-1751
DOI 10.1111/liv.13216, PubMed 27864874
Elevated interleukin-8 in bile of patients with primary sclerosing cholangitis
Liver Int, 36 (9), 1370-7
DOI 10.1111/liv.13092, PubMed 26866350
Publications 2015
Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis
Hepatology, 62 (1), 188-97
DOI 10.1002/hep.27825, PubMed 25833813
Publications 2013
Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis
Aliment Pharmacol Ther, 39 (3), 282-301
DOI 10.1111/apt.12581, PubMed 24372568
Carboxyl-ester lipase maturity-onset diabetes of the young is associated with development of pancreatic cysts and upregulated MAPK signaling in secretin-stimulated duodenal fluid
Diabetes, 63 (1), 259-69
DOI 10.2337/db13-1012, PubMed 24062244
Absence of diabetes and pancreatic exocrine dysfunction in a transgenic model of carboxyl-ester lipase-MODY (maturity-onset diabetes of the young)
PLoS One, 8 (4), e60229
DOI 10.1371/journal.pone.0060229, PubMed 23565203
Publications 2011
The role of pancreatic imaging in monogenic diabetes mellitus
Nat Rev Endocrinol, 8 (3), 148-59
DOI 10.1038/nrendo.2011.197, PubMed 22124438
Diabetes and pancreatic exocrine dysfunction due to mutations in the carboxyl ester lipase gene-maturity onset diabetes of the young (CEL-MODY): a protein misfolding disease
J Biol Chem, 286 (40), 34593-605
DOI 10.1074/jbc.M111.222679, PubMed 21784842
Publications 2010
Pancreatic function in carboxyl-ester lipase knockout mice
Pancreatology, 10 (4), 467-76
DOI 10.1159/000266284, PubMed 20720448
Publications 2008
Lack of pancreatic body and tail in HNF1B mutation carriers
Diabet Med, 25 (7), 782-7
DOI 10.1111/j.1464-5491.2008.02460.x, PubMed 18644064
Reduced pancreatic volume in hepatocyte nuclear factor 1A-maturity-onset diabetes of the young
J Clin Endocrinol Metab, 93 (9), 3505-9
DOI 10.1210/jc.2008-0340, PubMed 18593771
Neurological features and enzyme therapy in patients with endocrine and exocrine pancreas dysfunction due to CEL mutations
Diabetes Care, 31 (9), 1738-40
DOI 10.2337/dc07-2217, PubMed 18544793
Publications 2007
Pancreatic exocrine dysfunction in maturity-onset diabetes of the young type 3
Diabetes Care, 31 (2), 306-10
DOI 10.2337/dc07-1002, PubMed 17989309